Clinical reinvestigation and linkage analysis in the family with Episkopi blindness (Norrie disease)

G Wolff, A Mayerová, T F Wienker, P Atalianis, P Ioannou, M Warburg

Abstract
We present the results of a clinical and genetic re-investigation of the Cypriot family affected by an X chromosomally inherited eye disease originally published by Taylor et al, who coined the term Episkopi blindness. The pedigree was extended to 160 members, including 16 affected males out of 48 males at risk for the disease, most of whom were seen by one of us (PA). Affected males are blind with no associated symptoms and apparently are not mentally retarded. Thirty-nine family members agreed to blood sampling for genetic investigations. RFLP analysis was performed using probes from the region known to be deleted in some Norrie patients and polymorphic markers (DXS77, DXS7, MAOA, DXS255) from the proximal short arm of the X chromosome. There was no deletion for any of the probes. Linkage analysis yielded positive lod scores for all informative markers (Z (DXS255, \(0=0\)) = 6.54, \(Z (MAOA, 0=0) = 2.23, Z (DXS7, 0=0) = 1.3\)). Thus, the information that Episkopi blindness and Norrie disease (NDP, MIM *310600) are the same entity based on clinical evidence is now reinforced by gene mapping.

(J Med Genet 1992;29:816-9)

Norrie disease (ND) is an X linked recessive disorder characterised by blindness caused by the early development of retinal dysplasia, vascular proliferation (pseudoglioma), and ocular phthisis (MIM *310600). Over 300 cases have been described, about one third of which have additional symptoms such as sensorineural hearing loss, mental retardation, or psychotic behaviour. Close linkage has been shown between the disease locus (NDP) and DXS7 at Xp11.3 defined by probe L1.28. This brings the compiled lod score for linkage between NDP and DXS7 to 6.51 at \(\theta = 0.00.8\) Recombination events between these two loci have been reported by Ngo et al.

Several patients with Norrie disease have been reported who carry microdeletions encompassing DXS7. In the patient of Donnai et al, the deletion included DXS228 defined by probe 1A6. In the patients of Gal et al and de la Chapelle et al, the MAOA and MAOB genes were also shown to be deleted. Sims et al reported another deletion patient who uniquely retained the DXS7 locus while being deleted for MAOA and MAOB. In addition to the ophthalmic features the clinical picture in the deletion cases comprised one or more symptoms such as severe mental retardation, hypotonia, hypertelorism, microcephaly, cryptorchidism, and failure to thrive.

Taylor et al reported a six generation Greek Cypriot family with an apparently X linked blindness living in Episkopi in Cyprus, the disease therefore being popularly known as Episkopi blindness. This condition was thought to be another example of Norrie disease on clinical and genetic grounds by Warburg. The family was restudied clinically by Merin et al in 1972.

We performed a clinical re-investigation of the family and linkage analysis with DNA markers from the short arm of the X chromosome to test the identity of Episkopi blindness and Norrie disease.

Materials and methods

FAMILY AND PATIENTS
The family is personally known to one of us (PA). This allowed us to take the family history and to extend the pedigree to 160 members including 16 affected males out of 48 males at risk (Fig 1). Of the living affected males and obligate female carriers all but one each (VI.47, V.17) were seen. Unfortunately, neither the male patients nor the female obligate carriers were willing to see an ophthalmologist for thorough opthalmoscopic examination. Thirty-nine family members (including one husband of a potentially heterozygous woman) agreed to blood sampling for genetic analysis.

PROBES
The following probes were used in this study: L1.28 (TagI) defining DXS7, pX39 (EcoRV) defining DXS77, M27B (EcoRI) defining DXS255, MAOB (EcoRV) defining MAOA.

METHODS
Chromosomal DNA from peripheral blood cells were isolated using standard methods. After digestion with restriction enzymes according to the manufacturer’s specifications and separation on 0.8% agarose gels, the DNA was blotted onto Hybond N+ (Amersham) membranes and hybridised to a probe radio-
actively oligolabelled by the method of Feinberg and Vogelstein. Prehybridisation and hybridisation were performed at 65°C in 0.5 mol/l sodium phosphate, 0.001 mol/l EDTA, and 7% sodium dodecyl sulphate. Blots were autoradiographed after being washed with 0.02 mol/l sodium phosphate and 1% sodium dodecyl sulphate at 65°C.

Lod scores were calculated using the LIPED program, and multipoint linkage analysis was performed using the LINKMAP program, version 5.10, kindly provided by J Ott (fig 2).

Results and discussion
The pedigree, compared with that published by Taylor et al., could be extended by one generation and 66 family members (fig 1).

![Figure 1: Pedigree of the family, with Episkopi blindness as shown in table 2.](image)

![Figure 2: Multipoint linkage analysis using the LINKMAP program (version 5.1, provided by J Ott 1991). The vertical axis gives the location scores. Note the scale factor and offset. The horizontal axis is related to the marker map according to Mahtani et al. Locus DXS77 is not shown, because there is no significant contribution (table 3). The unusual shape of the location score curve results from the absence of recombination events in the Episkopi pedigree. Absence of interference is assumed and hence Haldane's mapping function is used.](image)

![Figure 3: Clinical features of V.9 at the age of 55 years.](image)
Ophthalmic symptoms in the affected are shown in table 1. All suffer from congenital blindness apart from three, who had some vision or light perception up to 3, 7, and 13 years of age. V.13 is blind after an accident with an insecticide spray at the age of 55. The clinical features of one of the patients (V.9) is shown in fig 3. A CT scan in another affected subject, who had some vision in the right eye and perception of light in the left up to 7 years of age, is shown in fig 4. This clearly shows the variability of expression of the gene defect. At the time of our investigation none of the living patients who were seen by us had mental or hearing defects, and none had any of the additional symptoms frequently observed in Norrie disease, especially in patients with microdeletions. Accordingly we did not find a microdeletion with the probes X.59, L.1.28, or MAO-A which are known to detect deletions in some of the patients with Norrie disease. A DNA probe 500 kb proximal to

<table>
<thead>
<tr>
<th>Pedigree No</th>
<th>Age at the time of this study</th>
<th>Side</th>
<th>Small eye</th>
<th>Diffuse corneal opacity</th>
<th>Band shaped corneal opacity</th>
<th>Cataract</th>
<th>Retrolental opacity</th>
<th>Amaurosis (V = vision, PL = perception of light)</th>
</tr>
</thead>
<tbody>
<tr>
<td>V.4</td>
<td>72</td>
<td>R</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>V.9</td>
<td>55</td>
<td>L</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>V.12</td>
<td>54</td>
<td>R</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>PL (13y)</td>
</tr>
<tr>
<td>V.19</td>
<td>45</td>
<td>R</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>V (9y)</td>
</tr>
<tr>
<td>V.21</td>
<td>41</td>
<td>L</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>V.25</td>
<td>63</td>
<td>L</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>V.29</td>
<td>53</td>
<td>L</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>VI.6</td>
<td>53</td>
<td>R</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>VI.14</td>
<td>35</td>
<td>R</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>VI.30</td>
<td>41</td>
<td>L</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>VI.47†</td>
<td>42</td>
<td>R</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

*Seen on ocular scans.
†Information quoted from Taylor et al.18

Figure 4 Cranial CT scan of VI.14 at the age of 35 years. He had some vision on the right up to 7 years and perception of light by the age of 7 on the left. Note on the left a small osseous orbit, a small globe with squamous calcification in a ring-like configuration, and a central, non-calcified area (A), and diminution of the optic nerve (B). On the right, spotty calcifications in the posterior segment of the eye (C) and a slight hyperdensity in the medial part of the lens (D) can be seen.
Clinical reinvestigation and linkage analysis in the family with Episkopi blindness (Norrie disease)

### Table 2: Marker haplotypes for four NDP linked loci segregating in the family.

<table>
<thead>
<tr>
<th>Locus</th>
<th>Probe</th>
<th>Enzyme</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXS7</td>
<td>X59</td>
<td>EcRV</td>
</tr>
<tr>
<td>DXS7</td>
<td>L1.28</td>
<td>Taq</td>
</tr>
<tr>
<td>MAOA</td>
<td>MAOA-A</td>
<td>EcRV</td>
</tr>
<tr>
<td>DXS255</td>
<td>M27β</td>
<td>EcR1</td>
</tr>
</tbody>
</table>

#### Enzymes:
- EcRV
- Taq
- EcR1

<table>
<thead>
<tr>
<th>Locus</th>
<th>a</th>
<th>b</th>
<th>c</th>
<th>d</th>
<th>e</th>
<th>f</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXS7</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>DXS7</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>MAOA</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>DXS255</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>2</td>
<td>4</td>
</tr>
</tbody>
</table>

### Table 3: Lod scores of main locus and marker, calculated using the LIPED program.

<table>
<thead>
<tr>
<th>Locus</th>
<th>NPD</th>
<th>Locus</th>
<th>(\theta)</th>
<th>(\hat{\theta})</th>
<th>Z((\hat{\theta}))</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXS7</td>
<td>2.13</td>
<td>DXS7</td>
<td>0.00</td>
<td>0.05</td>
<td>0.10</td>
</tr>
<tr>
<td>MAOA</td>
<td>0.04</td>
<td>DXS255</td>
<td>0.20</td>
<td>0.30</td>
<td>0.40</td>
</tr>
<tr>
<td>DXS7</td>
<td>6.54</td>
<td>MAOA</td>
<td>0.00</td>
<td>0.05</td>
<td>0.10</td>
</tr>
<tr>
<td>DXS255</td>
<td>5.05</td>
<td>MAOA</td>
<td>0.00</td>
<td>0.05</td>
<td>0.10</td>
</tr>
<tr>
<td>DXS7</td>
<td>5.13</td>
<td>MAOA</td>
<td>0.00</td>
<td>0.05</td>
<td>0.10</td>
</tr>
</tbody>
</table>

L.1.28 also failed to detect a deletion in one of the affected males (T. Meitinger, personal communication).

Results of DNA haplotyping are shown in fig 1 and table 2. As can be seen the phenotype 'Episkopi blindness' cosegregates with the 'a' haplotype. There is only one crossover between DXS255 and MAOA in V.26, indicated as b/h haplotype. Linkage analysis yielded positive lod scores for all markers segregating in an informative fashion (table 3). Thus, the identity of Episkopi blindness and Norrie disease is supported by gene mapping. DXS255 (probe M27β) gives the highest lod score (6.54 at \(\theta = 0.00\)) only because it is the most informative marker and there are no recombinations between NDP and any of the markers used. Clearly, the Norrie disease locus must be located in close proximity to the MAOA locus.

Our result will enable effective genetic counselling and heterozygote detection in the family. Further analysis with other probes located in the region of interest and finally mutation analysis of the as yet unidentified gene itself will prove the hypothesis that in this family with Episkopi blindness we are dealing with a mutation within the Norrie disease gene.

We thank Professor Schumacher from the Radiologische Universitätsklinik Freiburg, Sektion Neuroradiologie, for the interpretation of the CT scans, and Mrs Wurich for excellent secretarial assistance.

Clinical reinvestigation and linkage analysis in the family with Episkopi blindness (Norrie disease).
G Wolff, A Mayerová, T F Wienker, P Atalianis, P Ioannou and M Warburg

doi: 10.1136/jmg.29.11.816

Updated information and services can be found at:
[http://jmg.bmj.com/content/29/11/816](http://jmg.bmj.com/content/29/11/816)

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)